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Abstract
The ability of a cell to conserve and maintain its native DNA sequence 
is fundamental for the survival and normal functioning of the whole 
organism and protection from cancer development. Here we review 
recently obtained results and current topics concerning the role of the 
ataxia-telangiectasia mutated (ATM) protein kinase as a damage sensor 
and its potential as therapeutic target for treating cancer. This monograph 
discusses DNA repair mechanisms activated after DNA double-
strand breaks (DSBs), i.e. non-homologous end joining, homologous 
recombination and single strand annealing and the role of ATM in the 
above types of repair. In addition to DNA repair, ATM participates in a 
diverse set of physiological processes involving metabolic regulation, 
oxidative stress, transcriptional modulation, protein degradation 
and cell proliferation. Full understanding of the complexity of ATM 
functions and the design of therapeutics that modulate its activity to 
combat diseases such as cancer necessitates parallel theoretical and 
experimental efforts. This could be best addressed by employing a 
systems biology approach, involving mathematical modelling of cell 
signalling pathways.
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1. Introduction
1.1. Mechanisms of Eukaryotic DNA repair
Conservation and protection of the native DNA sequence and structure is 
essential for the survival and normal functioning of a cell and ultimately of 
the whole organism.  However, our bodies are constantly exposed to diverse 
types of genotoxic insults from various sources that can damage cellular 
DNA and threaten the survival. The causes and sources for DNA damage 
can be both exogenous and endogenous. Major exogenous sources include 
exposure to ionizing radiation e.g. UV, X-rays, gamma rays [1, 2] and 
through contact with certain chemical carcinogens. Endogenous means of 
DNA damage may include generation of reactive oxygen species resulting 
from metabolic by-products during cellular respiration, mechanical 
damage to chromosomes e.g. when dicentric or catenated chromosomes 
are pulled to opposite poles during mitosis, during programmed genomic 
rearrangements induced by nucleases and defective metabolism of 
chromosomal ends [3]. The different sources of DNA damage can cause a 
wide variety of DNA lesions. For example, ionizing radiation can induce 
single or double stranded DNA breaks (SSBs or DSBs respectively), 
UV light can cause the formation of pyrimidine dimers or depurination, 
chemical carcinogens can cause DNA cross links, enzyme-mediated base 
removal may produce abasic sites, and spontaneous cytosine deamination 
can result in non-native DNA base, uracil. Additionally, replication fork 
arrest caused by SSBs can result in its collapse and creation of DSBs [4]. 
In most of the instances, generation of DNA lesions causes structural and 
functional changes in DNA that can accumulate through cell division and in 
extreme cases, leads to cancer and death. Generation of DSBs is generally 
regarded as the most toxic of all DNA lesions while its repair, as the most 
complex process [5]. Errors in the repair of DSBs can result in deletion or 
insertion mutations, chromosomal translocation, and genomic instability 
leading to malignancy [6]. 
 In order to maintain genomic integrity, eukaryotic cells have 
developed intricate DNA damage sensing and repair mechanism that 
combats the diverse sources of DNA damage and ensures survival. 
Critical features of this highly robust repair mechanism are the ability 
to specifically recognize the DNA lesion and efficiently remove it. 
Additionally, the different repair responses that are generated and the 
resulting network signalling triggered within the cell not only repairs the 
DNA lesion, but is also tightly linked with the cellular machinery that 
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Figure 1. Cellular responses to DNA damage. Depending upon the scale of DNA 
damage, one of the two pathways may be activated. If the DNA damage is minor, sensor 
proteins are activated, which recruit specialized DNA repair enzymes to the damaged 
site and DNA is repaired. However, if the DNA damage is extensive, the DNA Damage 
Response (DDR) pathway is activated , which triggers specialized transducer proteins that 
amplify the damaged signal and activate effector proteins. The effector proteins cause cell 
cycle arrest and increase in the production of DNA damage repair enzymes. The arrest at 
the cell cycle checkpoints may result in temporary halting of the cell cycle, a permanent 
arrest or induction of apoptotic pathways. Source - Khalil HS et al. [10]. 
governs cell-fate decision e.g. cell cycle arrest to promote survival or 
programmed cell death. DNA repair capacity and response depends on 
the differentiation state of the cell and the scale and type of damage [7-
9]. Depending upon the scale and type of DNA damage, different repair 
responses can be activated with different outcomes for the cell. Figure 
1 shows a simplified illustration of different components of the repair 
pathway and its effects on cell-fate. 
 There are six damage-type-specific repair mechanisms that can be 
triggered for dealing with different kinds of DNA damage. Table 1 shows the 
different types of DNA damage and the type-specific DNA repair mechanism 
that is activated as a result of it. 
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Table 1. Types of DNA damage and the mechanism of its repair. 
Type of DNA damage Repair mechanism
Methylated (O6 or N7) Guanine Direct repair
Oxidised/Deaminated bases Base excision repair
Bulky DNA lesions, DNA-protein adducts Nucleotide excision repair
Mismatched bases Mismatch repair
Double stranded DNA breaks Non-homologous end joining
Double stranded DNA breaks Homologous recombination
Double stranded DNA breaks Single strand annealing
 Since this monograph focuses on regulation and functional 
elucidation of ATM, a protein kinase involved in DSB repair, DNA repair 
mechanisms activated only after DSBs, i.e. non-homologous end joining, 
homologous recombination and single strand annealing will be discussed in 
more detail. 
1.2. Double stranded DNA repair
1.2.1. Non-homologous end joining (NHEJ) DNA repair
This mode of DNA repair is often described as error-prone. Double stranded 
breaks produced by nucleases or after exposure to ionizing radiation (IR) 
are often repaired by this mechanism [4]. It is thought to be the predominant 
type of repair mechanism of DSBs in mitotically replicating cells and has 
been studied in greater detail. The hallmark of NHEJ is its ability to ligate 
non-ligatable DNA ends.
 In this mechanism, after the generation of DSBs, a heterodimeric 
protein called KU comprising of KU70 and KU80 subunits, binds to the 
ends of DNA breaks and occupies a region of 16-18bp [11]. This heterodimer 
next recruits its catalytic subunit called DNA-PKcs to the DNA end which 
displaces the KU dimer to the inside and binds at the extreme ends of broken 
DNA [12].  This results in the formation and activation of trimeric DNA-PK 
holoenzyme, a key kinase in NHEJ repair [13]. Once this kinase is activated, 
it recruits and phosphorylates key DNA damage repair proteins including 
WRN, which is a 3’ to 5’ exonuclease [14], the Artemis factor, which has 
specific 5’ to 3’ exonuclease as well as endonucleolytic activity on 5’ and 3’ 
hairpins and overhangs [15] and the replication protein A (RPA) which binds 
and subsequently stabilizes single-stranded DNA intermediates formed 
during DSBs and thus prevents complementary DNA from reannealing [16]. 
 The recruited exonucleases can digest and process the damaged 
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DNA ends for ligation. Next, DNA-PK phosphorylates XRCC4, a binding 
partner of DNA ligase IV, which is then recruited to the damaged DNA ends. 
DNA polymerases POLμ or POLl are next involved in filling the DNA 
gaps produced by the damage [17] while XRCC4-Ligase IV complex seals 
the nicks [18]. DNA-PK also autophosphorylates itself, which causes its 
detachment from the DNA lesion [19]. A simplified cartoon version of the 
Figure 2. Double stranded DNA repair via Non-homologous end joining (NHEJ). After 
DNA undergoes double stranded breaks, it may be repaired in an error prone mechanism 
via NHEJ. The DNA breaks are first detected by KU subunits which recruit DNA-PK 
catalytic subunit and assemble DNA-PK holoenzyme. This results in the recruitment of 
specific endonucleases that carry out DNA ends processing for subsequent ligation, DNA 
polymerase μ or λ to fill in the gaps and XRCC/LigIV complex to seal the DNA nicks. The 
Figure is designed on the basis of information from [11, 12, 15]. 
entire process of DNA repair mediated by NHEJ is depicted in figure 2. 
1.2.2. Homologous Recombination repair (HRR)
This mode of DNA repair is referred to as error-free mechanism. DNA 
damage caused by either IR or replication fork arrest are primarily repaired 
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by this mechanism. The reason why greater repair accuracy is achieved 
with this mechanism is because of the use of homologous sequences in 
the genome e.g. sister chromatids, homologous chromosomes or repeated 
regions, to prime the repair synthesis. For this reason, HRR is most active 
in late S/G2 phase of the cell cycle [20]. The fact that HRR can use 
homologous chromosomes as a template for the resynthesis of damaged 
DNA, wich can result in loss of heterozygosity, is an important feature 
of HRR repair. 
 The HRR process is triggered by the generation of DSBs primarily 
post S phase. This is followed by extensive 5’ to 3’ end processing 
resulting from the activities of the recruited exonucleases i.e. MRE11, 
present as a complex in MRE11/Rad50/NBS1, collectively called MRN 
complex [21] and WRN [22]. Additional roles of MRN complex are also 
presumed namely: recruitment of the key protein kinase in DSB repair 
known as ATM, via its NBS1 subunit, which is known to be a substrate 
for ATM phosphorylation [23] and unwinding DNA via ATPase activity 
of its Rad50 subunit [24]. After the 5’ to 3’ resection, the exposed single 
strands recruit RPA protein, which coats the resected single stranded DNA 
and also recruits RAD51 [25]. RAD51 forms nucleoprotein complexes 
on RPA-coated single stranded DNA to initiate strand exchange, with 
the help of its five paralogues, RAD51B, C, D, XRCC2 and XRCC3. 
The resulting nucleoprotein filament searches the nearby sequences to 
find a homologous sequence which is later invaded with the help of 
RAD54, an ATPase related to DNA helicases [26]. This is followed by 
the recruitment of RAD52 which forms a seven-monomer ring structure 
at the nucleoprotein filament that can interact with both double and 
single stranded DNA [27].  Additionally, breast cancer susceptibility 
genes, BRCA1 and BRCA2 are also recruited to the site, which can act as 
scaffolding proteins and may also interact with RAD51 and RPA [28]. 
 All these initial events result in stand invasion of the DNA 
overhangs and pairing with homologous sequences. Using this 
homologous sequence as a DNA template, DNA polymerase starts filling 
the gaps of the resected 5’ to 3’ DNA ends of the damaged homologue. 
At this point, there is a formation of an intermediate DNA structure, 
called Holliday junction [29]. During HRR, this Holliday junction can 
be resolved either by disengagement of the two pairs of strands resulting 
in a non-crossingover mode of HRR, or via its endonucleolytic cleavage 
mediated by resolvases resulting in a crossover mode [5]. Finally, the 
DNA ends are ligated. The DNA polymerase and the ligase involved in 
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Figure 3. Double DNA break repair via Homologous Recombination (HR). After 
DNA undergoes DSBs, it may be repaired via HR. The DNA with DSBs is shown in 
black, the DNA from sister chromatid or homologous chromosome is shown in orange 
while the newly synthesised DNA is depicted by blue dashed lines. In this mechanism 
of error free repair, the DSBs recruit MRN complex, which has exonuclease and ATPase 
activity via its MRE11 and RAD50 subunits respectively and which may recruit ATM via 
its NBS1 subunit. Resection of DNA strand results in recruitment of RPA, which further 
recruit Rad51, its paralogues and Rad54, together forming nucleoprotein complex at the 
site of damage. Recruitment of Rad52 commences homology search and strand invasion, 
which can result in the formation of D-loop structure. Unknown DNA polymerases 
extend the resected DNA strands using homologous sequences as template which results 
in the formation of Holliday junction. The Holliday junction may be resolved either in 
crossingover or non-crossingover fashion and the nicks are sealed by DNA ligases. The 
figure is designed based on information from [23, 24, 26, 29].
HRR are as yet unknown. The entire scheme of DNA repair via HRR 
pathway is illustrated in figure 3.
1.2.3 Single strand annealing (SSA)
Single strand annealing is a non-conservative process of DNA repair of 
DSBs. In this process, when DNA breaks are produced, DNA resection 
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takes place most likely by the exonuclease activity of MRN complex. The 
length of the resected DNA, and hence of the DNA overhangs, depends 
upon how far up within DNA sequence, homology is found within direct 
repeats. Once homology with either of the two DNA overhangs is found, 
strand annealing takes place at those homologous regions, while the rest of 
the non-homologous sequences are cleaved [5]. Repair via SSA does not 
require RAD51. However, for the purpose of homology search, heptameric 
RAD52 ring formation still takes place. ERCC1/XPF nuclease is known to 
Figure 4. Double DNA break repair via Single Strand Annealing (SSA). After DNA 
undergoes DSBs, it may be repaired in a non-conservative mechanism via SSA. MRN 
mediated resection of damaged DNA ends causes recruitment of RPA, which coat the 
resulting single strands and recruits Rad52 that commences search for homology sequence 
in the direct repeats. ERCC1 causes endonucleolytic cleavage following by gap filling and 
ligation. This mode of repair results in loss of DNA sequence and hence known as non-
conservative DNA repair. The Figure is designed based on information from [5, 30].
be involved in the endonucleolytic activity [30]. Finally, the gaps are filled 
with DNA polymerase and followed by ligation of DNA ends. Figure 4 
shows the scheme of repair via SSA. 
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Figure 5. The DNA damage pathway and its crosstalk with the cell cycle. Lines with 
arrow heads represent activation while lines with bar heads represent deactivation, dashed 
lines with arrow heads indicate activation via phosphorylation and dashed lines with 
bar heads denote phosphorylational inactivation. Grey lines with arrow heads represent 
dephosphorylation. After DNA damage, P53 and checkpoint kinases Chk1/Chk2 proteins 
are activated. P53 activation results in concomitant rise in the CIP/KIP proteins, P21 
and P27 which inhibit cyclin/CDK complexes, blocking the cell cycle progression 
which results in G1/S arrest. The activated chk1/chk2 kinases activate Wee1, a protein 
kinase as well as inhibit the function of Cdc25 group of phosphatases, which normally 
dephosphorylate and activate cyclin/cdk complexes. The inactivation of cyclinB/CDK1 
activity via both phosphorylational inactivation by wee1 as well as inhibition of its 
activating phosphatases by Chk1/Chk2 result in G2/M arrest.  Thus in a normal cell, 
both G1/S and G2/M checkpoints are functional and may arrest the cell cycle upon DNA 
damage, to allow time for DNA repair.  Source Khalil HS et al. [10].
 As illustrated in figure 1, cellular responses generated after genotoxic 
insults not only depend on the type of DNA damage and the associated repair 
mechanism, but also on the scale or magnitude of a particular damage. Hence, 
if damage is of a lower scale, DNA damage sensors, e.g. KU subunits, MRN 
complex or WRN would detect the damage and recruit specialized repair 
enzymes as mentioned above to efficiently repair the damage. However, if 
there is an extensive DNA damage, with an impact on the entire cellular 
physiology, the cellular machinery governing cell-fate decision is mobilized. 
These signalling responses that are triggered after extensive DNA damage 
not only activate and recruit repair enzymes, but also give rise to a pathway 
called DNA Damage Response (DDR) pathway [31]. The most important 
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function of this pathway is to link the signalling generated in response to 
DNA damage with the cell cycle signalling pathway. Figure 5 represents a 
simple illustration of this link.  
2. Ataxia-telangiectasia mutated (ATM)
The DDR pathway has evolved to be a complex, yet sensitive, highly 
integrated and interconnected pathway which can trigger cellular responses 
including DNA repair, cell cycle arrest and apoptosis [32]. Central to DDR 
is the Ataxia telangiectasia mutated gene that codes for Ataxia telangiectasia 
mutated protein (ATM), a 370 kDa Serine/Threonine kinase, functioning 
as a core component of the DDR signalling pathway [33]. ATM belongs 
to phosphatidylinositol-3 kinase like kinase (PIKK) super family of large 
proteins having phosphatidylinositol-3/4 kinase (PI3K/PI4K) catalytic 
domain thus functioning as an important kinase in DDR signal transduction. 
It acts as a sensor of DSBs and through its kinase function, is responsible for 
the initiation of a signalling cascade by activating other downstream signal 
transducers and effector proteins of the DDR pathway. These effectors in 
turn modulate cell cycle progression, recruit DNA repair enzymes and may 
also trigger apoptosis if the DNA damage is beyond the repair capacity of 
the cell. Hence, ATM links responses generated by DNA damage with cell 
cycle progression and apoptotic pathways. This represents a very important 
function as in conditions of extensive DNA damage, cell cycle must be 
temporarily halted to allow adequate time for recruitment of DNA repair 
proteins and the actual repair of DNA. This ensures the integrity of genomic 
DNA and overall health and survival of dividing cells and prevents partially 
repaired DNA to pass on to daughter cells. Alternatively, ATM signalling may 
lead to permanent arrest of cell cycle, or in extreme cases to trigger apoptosis 
[34]. ATM and other members of the PIKK family are also involved in DNA 
replication and recombination, and homologous repair during normal meiotic 
recombination events [35].  
2.1 The ATM gene
The ATM gene is located on chromosome 11 (11q22-23) as determined via 
linkage analysis [36].  It belongs to the class of housekeeping genes [37]. 
The full genomic organization along with intron-exon boundaries was 
determined by [38]. ATM gene consists of 66 exons which span around 150 
Kb of the whole genomic DNA, with a coding sequence of 9168bp [39]. 
The entire ATM contig shows a low GC content of 38.1% [40]. The first two 
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exons are termed 1a and 1b. The initiation codon lies in exon 4 and the last 
exon which is 3.8 kb is the largest [38]. The first 4 exons of the ATM gene, 
which lie in the 5-UTR have been found to undergo extensive alternative 
splicing. Apart from that, the 3.6 Kb long 3-UTR, spreading across the last 
exon, also possesses alternative polyadenylation sites [38]. This results in 
generation of different mRNA transcripts having varying sequences and 
lengths. It has been suggested that the different UTRs within ATM mRNA 
transcripts may have important regulatory roles via the formation of different 
secondary structures and varying number of AUG codons [41].  
 Because of the sheer size of the ATM, special cloning and expression 
vectors were required for its clonal manipulation. The first successful attempt 
to clone the whole ATM gene, via positional cloning, dates back to 1995 [33]. 
Other attempts to clone either its cDNA fragments coding only the kinase 
domain of ATM [42] or full length ATM [43] quickly followed. Shortly 
after the successful cloning of the full length ATM cDNA, several groups 
developed mouse models of a dysfunctional ATM that helped elucidate 
different functional aspects of ATM [44, 45]. 
2.2 ATM promoter regulation
ATM shares a bi-directional promoter with another housekeeping gene called 
NPAT which lies around 0.55kb upstream of the ATM start codon. NPAT is 
required for progression through G1/S and entry into S phase of the cell 
cycle and has also been shown to positively regulate ATM [46]. The ATM 
side of the promoter activity is found to be 3 times stronger than on the NPAT 
Figure 6.  ATM promoter sequence and cis-regulatory elements [48].
5’GCTTCCCTACCAAGGGAAAACCTTTGGCCTCAAAGGTCCTTCTGTCCAGC
ATAGCCGGGTCCAATAACCCTCCATCCCGCGTCCGCGCTTACCCAATACAAG
CCGGGCTACGTCCGAGGGTAACAACATGATCAAAACCACAGCAGGAACCACA
ATAAGGAACAAGACTCAGGTTAAAGCAAACACAGCGACAGCTCCTGCGCCGC
ATCTCCTGGTTCCAGTGGCGGCACTGAACTCGCGGCAATTTGTCCCGCCTCT
TTCGCTTCACGGCAGCCAATCGCTTCCGCCAGAGAAAGAAAGGCGCCGAAAT
GAAACCCGCCTCCGTTCGCCTTCGGAACTGTCGTCACTTCCGTCCTCAGACT
TGGAGGGGCGGGGATGAGGAGGGCGGGGAGGACGACGAGGGCGAAGAGGGTG
GGTGAGAGCC 3’
Sp1 sites
cAMP responsive element
CAAT boxes
Insulin responsive element
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side [47]. This promoter region has been found to be TATA-less, has CCAAT 
boxes and several other important promoter sites including CREB, SP1, AP-
2, GCF [48, 49]. Full sequence of the characterised ATM promoter region 
and details of its cis-regulatory elements are shown in figure 6. 
 There is some evidence of the existence of another putative promoter 
region immediately upstream of the first coding exon which also possesses 
TATA box [50]. This may contribute in the basal level expression of the 
ATM gene. In the past, several researchers including our group have targeted 
the ATM promoter region to study its activity or elucidate ATM expression 
patterns [51-56]. While ATM is generally regarded as a constitutively 
expressed gene with no major change in its overall expression, it has been 
found that the promoter activity is tissue specific, and shows an induction of 
transcription in certain conditions [51, 52]. 
 A higher induction is seen in tissues with lower basal level of ATM 
and vice versa [57]. Moreover, some tissues show higher protein expression 
without any changes to mRNA levels suggesting a translational control rather 
than promoter regulation [58]. 
2.3 ATM protein: Domains, post-translational modification and 
expression 
ATM is expressed as nuclear 3056 amino acid-long Serine/Threonine protein 
kinase [43, 59]. The 3-D crystal structure of this protein is as yet, unknown. 
However through protein sequence analysis and homology determination, 
several protein domains have been identified in ATM. 
 The kinase function of ATM is maintained by 350 residues long, 
PI3K/PI4K domain spreading between amino acids 2712 to 2962. It also 
contains a FAT domain (name derived from FRAP, ATM and TRRAP) at 
region 1960 to 2566 amino acids and a C-terminal FAT domain (FATC 
domain) between residues 3024 and 3056 [60]. Apart from that, a leucine 
zipper motif between residues 1217—1238 [33, 60] and a ten amino acids 
long, proline rich c-Abl (a tyrosine kinase) interacting region between 
residues 1373 – 1382 have been identified [61]. Figure 7 shows the domain 
architecture of ATM protein along with their associated functions. 
 ATM is a constitutively expressed protein, which is held in an 
inactive homodimeric or higher order multimeric state. In this form, the 
kinase domain of one molecule is buried in a region surrounding the residue 
serine 1981 of the partner monomer. Upon genomic insults e.g. exposure 
to ionizing radiation, the pre-existing ATM molecules undergo rapid 
autophosphorylation at residues Ser367, Ser1893 and Ser1981, the last serine 
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Figure 7. The domain architecture of ATM and the associated functions. The 3056 
amino acid long ATM protein has been shown to have a FAT domain, a kinase domain 
and FATC domain at the extreme C-terminal. The 251 amino acid long, C-terminal kinase 
domain of ATM classifies it in the PIKK superfamily of protein kinases. Source Khalil 
HS et al. [10].
being in the FAT domain [62, 63]. This autophosphorylation results in dimer or 
oligomer dissociation and the release of kinase active monomers [62]. These 
monomers have exposed N-terminal sequences to bind to their substrates 
while C-terminal kinase domain for their subsequent phosphorylation. DNA 
damage-induced full activation of ATM also involves acetylation of Lysine 
Table 2. ATM phosphorylational mapping [10].
Residue modified Position Reference
Serine 72 [67]
Serine 85 [67]
Serine 86 [67]
Serine 367 [63]
Serine 373 [67]
Serine 1883 [69]
Serine 1893 [63]
Serine 1981 [62]
Serine 1985 [67]
Serine 2996 [68]
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3016 present in the FATC domain by Tip60 histone acetyltransferase [64, 
65]. The complete list of phosphorylated ATM residues determined so far is 
given in table 2. However, of those listed, only the autophosphorylation sites 
at Serine 367, 1893 and 1981 have been fully characterised and play a role 
in ATM activation [62, 63, 66]. The remainder of the phosphorylation sites 
were identified through large scale proteomic analysis [67-69] and their role 
in regulating the function of the protein warrants further study.
 In terms of its expression, ATM is regarded as a housekeeping gene 
with predominantly nuclear localisation and a steady constitutive expression 
[70]. ATM maintains basal levels of phosphorylated ATM at serine 1981. 
ATM expression and localisation in human keratinocytes is shown in figure 
8. At an organism level, it is ubiquitous and is expressed in several embryonic 
and adult tissues [71]. However, the overall expression varies from organ 
Figure 8. Expression and localisation of ATM and phosphor-ATM (serine 1981) 
in HaCat cells. Cells were grown on poly-L lysine coated coverslips for 18 hours and 
transfected with N-terminal YFP tagged ATM. 24 hours later, cells were fixed, permeabilized 
and subjected to immunofluorescence by labelling with anti-phospho-ATM  (serine 1981) 
antibody and Alexa fluor 568 conjugated secondary antibody (Invitrogen). Scale bar 
represents 8μm. Source - Khalil HS et al. [75].
to organ. High expression has been observed in developing nervous system 
[72, 73], spleen, thymus and testis [53, 71]. Additionally, higher amounts are 
also seen in those tissues which undergo frequent proliferation and genetic 
recombinations to ensure the genomic integrity [57, 74]. 
 ATM is regarded as the caretaker of the genome [76] and apart 
from being activated after genomic insults, is also thought to be involved in 
oxidative stress response [77, 78] (more details in section 5). 
 In keeping with its role as a constitutively expressed gene, ATM 
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Figure 9. ATM levels change during progression of the cell cycle. Total and pATM levels 
and its substrates total and phospho Chk2 T-68, total and phospho E2F1 S-31 and total 
and phospho P53 S-15 change through the cell cycle in MCF10A human epithelial cell 
line.  Cells were grown till 70% confluence and serum starved for 48 hours. Serum was 
added back and cells were allowed to grow for the indicated time points following serum 
stimulation. The data is based on optical densitometry analysis of immunoblotting.
protein level is generally believed to remain constant within the cells. It has 
been reported that ATM does not undergo any change in its total protein levels 
after DNA damage, with the only change being dimer to monomer transition 
and activation of its kinase activity [62, 79]. ATM expression was earlier 
also reported to remain constant throughout the cell cycle. Furthermore, 
following genotoxic insults, no major change in its sub-cellular localisation 
had been observed initially after its discovery [80].
 However, few years later, contrary reports emerged demonstrating 
an alteration in ATM protein expression under certain circumstances 
accompanied by a corresponding change in ATM activity. In one study, 
radiation-induced upregulation of ATM in situ and in response to mitogens 
resulting in increased ATM kinase activity was reported [81]. By contrast, 
epidermal growth factor was reported to down-regulate ATM at the 
transcriptional level [55]. Furthermore, we have shown that the total and 
phosphorylated levels of ATM underwent cell cycle dependent changes in 
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MCF10A cell line (figure 9). 
In most of these instances, alterations in the amount of ATM protein 
resulted in variation in its activity, ultimately impacting cellular sensitivity 
towards genotoxic agents. Promoter studies of ATM further revealed radiation 
inducibility [54] and tissue-dependent variation in expression in vivo [53]. 
In addition recently it has been shown that BRCA1/E2F1/CtIP binding to 
ATM promoter activates ATM transcription [82]. Finally, recently we have 
reported a link between ATM activity and its expression via promoter studies 
[51, 83]. All these later discoveries challenged the earlier belief of ATM 
gene to be a constitutively expressed gene and indicated the presence of 
additional mechanisms through which ATM expression and activity could be 
modulated, apart from the mere dimer to monomer transition event.
2.4. The ATM signalling pathway and its role in DNA damage response
As mentioned earlier, ATM is present at a nodal point in the DDR pathway, 
Figure 10. The ATM pathways and their associated consequences on cell-fate. ATM 
is present at the core of DNA damage pathway, activated upon DSBs and functions via 
multiple routes. While great deal of cross-talk exists between individual pathways, its 
major downstream substrates for DNA repair are MRN complex, BRCA1, RAD51and, 
P53, for cell cycle arrest are SMC1, CIP/KIP family of proteins via P53 and checkpoint 
kinases, for chromatic remodelling are Chk1 and for apoptosis are c-Abl, P53, Chk2, 
E2F1, P73 and NFkB. Source - Khalil HS et al. [10]. 
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Table 3.  ATM substrates in different phases of the cell cycle. Table is based 
on data  from  [10, 85- 87, 90].
Phases of the cell cycle
G1 G1/S S G2/M
P53
Mdm2
Nbs1
P53
cAbl
Rad51
RPA 
Chk2
FANCD2
H2AX
BRCA1
CtIP
MRN
Chk1
Chk2
Rad17(RFC)
and has the ability to trigger variety of cellular responses including DNA 
repair, cell cycle arrest and apoptosis in nuclear cells. ATM, as a DSBs sensor, 
not only ensures upregulation of repair enzymes followed by prompt DNA 
repair, but also signals to a variety of other key proteins with a consequence 
on cell-fate. This important link between DNA damage, the cell cycle 
progression and cellular apoptotic machinery is provided by ATM function 
and is illustrated in figure 10. 
 Since ATM function is implicated in a number of responses resulting 
from DNA damage, it needs to interact in a timely manner with a variety of 
downstream effectors. These interactions induce various signalling functions 
such as checkpoint arrest with P53, Mdm2 and Chk2 in the G1 [84-86] 
damage induced S-phase arrest with NBS1, BRCA1, FancD2 and SMC1 
[87-90] G2/M arrest with BRCA1 and hRad17 [91, 92] and apoptosis with 
E2F1, Chk2, P53, P73 and Bax [91-97]. Table 3 shows a classification of 
ATM substrates with respect to their roles in influencing different phases of 
the cell cycle. 
 Once DNA damage causes DSBs, a change in the higher order of 
chromatin structure is inflicted, because of the unwinding and relaxation of 
the local DNA super-coil. This topological change in DNA results in the 
exposure of a variant form of histone H2A, called H2AX [62]. The exposed 
H2AX is a substrate for ATM and is thought to trigger its activation. Activated 
ATM and the pre-existing constitutively active ATM phosphorylate H2AX at 
serine 139, further referred to as g-H2AX. H2AX is regarded as the earliest 
substrate of ATM after DSBs and hence g-H2AX formation represents one 
of the earliest events after DNA damage [98]. g-H2AX acts as a docking site 
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Figure 11. Nuclear foci formation of ATM following double stranded DNA damage. 
HaCat cells grown on Poly L lysine coated coverslips were either left untreated (UT) or 
treated with 0.5μM of Doxorubicin for 0.5, 2 or 4 hour (hr) time point. After fixation and 
permeabilization, cells were subjected to fluorescent immunolabelling by immunostaining 
total ATM using Alexa fluor 488 conjugated secondary antibody (Invitrogen). Accumulation 
of nuclear ATM foci formation is indicated by red arrows. Nuclear reference is provided by 
DAPI staining. Scale bar represents 8μm.
for variety of other proteins involved in the DNA damage response pathway 
which in turn recruit additional ATM molecules to amplify its signal and 
form discrete ATM foci at the broken DNA ends. Figure 11 shows such DNA 
damage induced foci formation in a human keratinocyte cell line exposed to 
a DSB inducing agent Doxorubicin [99]. A number of proteins are involved 
in the formation of such ATM foci. These proteins include MRN complex 
(composed of MRE11, RAD50 and NBS1), MDC1, RPA, RAD51, RAD52, 
RAD54, BRCA1 and BLM1 in the DNA repair component of DDR pathway 
[100]. 
 The  MRE11 component of the MRN complex executes 3’-5’ 
exonuclease activity, the RAD50 component maintains the broken ends intact 
and provides ATPase activity, that itself has endonucleolytic activity, while 
Nbs1 recruits and possibly triggers further activation of ATM molecules [21] 
which also undergo acetylation by Tip60 [65]. RPA phosphorylation by ATM 
is thought to divert its role from DNA replication to repair [101]. BRCA1 
is an important ATM substrate having multiple functions. It has a role in 
homologous repair by activating the enzyme Rad51. Its phosphorylation by 
ATM at residues Ser1423 and Ser1524 triggers its transcriptional activity 
causing increased transcription of P21 and GADD51, hence having a role in 
cell cycle arrest as well [102]. 
 BRCA1 is also thought to act as a scaffolding protein for the multiple 
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protein complexes that form discrete foci at the broken ends. Finally, ATM 
kinase activity for some of its substrate itself is dependent on BRCA1 protein 
[103]. 
 These initial events lead to generation of pool of active S-1981 
autophosphorylated ATM molecules that rapidly accumulate in the nucleus 
and amplify and transduce the signals to its effector molecules. DNA 
damage dependent nuclear pATM S1981 accumulation is shown in figure 
Figure 12. Nuclear accumulation of pATM S1981 following double-stranded DNA 
damage. HaCat cells grown on Poly L lysine coated coverslips were either left untreated 
(UT) or treated with 0.5μM of Doxorubicin for 0.5, 2 or 4 hour (hr) time point. After 
fixation and permeabilization, cells were subjected to fluorescent immunolabelling by 
immunostaining phospho ATM Serine 1981 using Alexa fluor 568conjugated secondary 
antibody (Invitrogen). Nuclear reference is provided by DAPI staining. Scale bar represents 
8μm.
12. Activated ATM also modulates the cellular machinery that determines 
the fate of the cell, other than the DNA repair component. ATM links the 
DNA damage response to cell cycle checkpoint arrest and apoptosis partly via 
the tumour suppressor protein P53. 
 ATM phosphorylates P53 at serine 15 that causes its increased 
stability and activation [84]. ATM also contributes in P53 activation via 
mdm2 phosphorylation at serine 395 that hinders mdm2 interaction with 
P53 [86]. Additionally, ATM phosphorylates both checkpoint kinases Chk1 
and Chk2 upon DNA damage [104, 105], which in turn phosphorylate P53 
on serine 20 and contribute further in its stabilization [106]. Once P53 is 
activated, it acts as transcriptional factor for important proteins including 
inhibitors of CDKs e.g. the CIP and KIP family of CDK inhibitors, P21/
waf1 and P27. As shown in figure 5, these bind and inhibit CDKs, an event 
which causes cell cycle arrest at G1/S phase. P53 also activates GADD45 
via which, it links itself to ATM induced DNA repair. Another downstream 
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target of ATM implicated in S-phase arrest is Fanconi anemia group D2 
protein (FANCD2) phosphorylated at Ser222 [88]. P53 is also responsible 
for causing apoptosis in ATM dependent manner [94]. 
 Apart from the above-mentioned role of the checkpoint kinases 
Chk1 and Chk2 in P53 stabilization, these effectors also phosphorylate 
Cdc25 phosphatases. Chk2 phosphorylates Cdc25A phosphatase at serine 
123 which causes its inactivation rendering it unavailable to dephosphorylate 
and activate CDKs, which otherwise cause cell cycle progression. This 
results in checkpoint arrest mainly at the G1/S phase [104]. Chk1 regulates 
the activities of Cdc25B by its phosphorylational inactivation and causes 
cell cycle arrest mainly in G2/M phase [107]. Furthermore, Chk1 also 
phosphorylates Cdc25C on serine 216 that serves as a binding site for 14-3-
3s protein, which sequesters it from nucleus [108] rendering it unavailable 
to dephosphorylate and activate cdk-cyclin complexes important for mitotic 
entry (fig. 5). 
 As illustrated in figure 10, ATM also plays a pivotal role in apoptotic 
induction both in P53 dependent and independent manner. Firstly, ATM can 
phosphorylate E2F1 on serine 31, which results in its increased stability 
and can cause apoptosis in P53 dependent manner [97, 109] as well as in 
an independent manner [110]. E2F1 can also undergo Chk2 dependent 
phosphorylation after DNA damage and trigger apoptosis [111]. Additionally, 
ATM dependent apoptosis can also be induced via Chk1 [112] 
 In a P53 independent mechanism, ATM can phosphorylate and 
activate c-Abl tyrosine kinase which via P73 dependent mechanism can 
induce apoptosis following extensive DNA damage [113].  Finally, ATM 
can also modulate apoptotic pathway following DNA damage, by stabilizing 
nuclear factor kappaB (NFkB) (reviewed in [114]). 
2.5. Protein trafficking during DDR
There is a vast amount of literature that aims to describe the functioning 
of DDR pathway from sensing the DNA damage to the recruitment of 
effector molecules and triggering the cellular machinery involved in cell-
fate decision making. While our understanding of the causes of cellular 
stresses that lead to DNA damage and their consequences for key events 
like transcriptional changes, post translational modification and the type of 
protein repair complexes that are assembled, has improved over the years, 
there are still gaps in our knowledge of DNA damage induced protein 
trafficking responses. However, only in the last decade, it has been realised 
that eukaryotic protein trafficking machinery, apart from facilitating the 
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processing, modification and secretion of nascent proteins, is also actively 
involved in different regulatory modalities and co-ordination of cell 
signalling and forms active component of key cellular decision making 
processes e.g. apoptosis, proliferation and cell cycle events. 
 Protein trafficking represents a very important constituent of 
eukaryotic cellular physiology. It is not only used to distribute newly 
synthesised and correctly folded proteins to their final destination, but also 
to facilitate transport of mature proteins from one sub-cellular compartment 
to the other for their proper functioning. In terms of DDR signalling, these 
trafficking events may take place to either provide association of DDR 
enzymes with their substrates, to sequester/bind a DDR transcription factor 
from/to its target promoter, or to prevent/allow complex formation between 
two proteins which would trigger or alter DDR signalling. Furthermore, 
within signalling pathways, intracellular protein trafficking events can also 
not only influence the overall signalling efficiency of a particular pathway, 
but can cause distinct compartmentalization of a multifunctional protein, a 
phenomenon that can lead to a bias in its downstream signalling event.
 In terms of DNA damage, the most critical function of the protein 
transport system is to concentrate the repair protein complexes at the site 
of DNA damage. This is expected to result in the translocation of multitude 
of proteins to the site of DNA lesion. This is a rapid process as indicated 
by the fast kinetics of g-H2AX phosphorylation and the resulting DNA 
foci formation, estimated to occur within minutes of DNA damage [115]. 
For this reason, protein trafficking events within the nucleus in response to 
DNA damage has received greater attention.  
 The role of protein trafficking in cell cycle progression is provided 
by a typical example of phosphorylation of Cdc25C by checkpoint kinases. 
Cdc25C phosphorylation at serine 216 by Chk1 creates a binding site 
for 14-3-3, which mediates its transport to the cytoplasm, sequestering it 
from its substrate, CyclinB-Cdk1 to prevent cell cycle progression [108]. 
Another example is the controlled nucleo-cytoplasmic shuttling of E2F1 
protein that is required for the progression of cell cycle [116]. Illustration 
of the importance of protein trafficking in the DNA repair component of 
DDR is provided by BARD1 protein, which is retained in the nucleus by 
BRCA1 resulting in DNA repair. In the absence of BRCA1, BARD1 is 
transported to cytoplasm where it triggers apoptotic signalling [117]. 
 P53 is widely characterised to shuttle between nucleus and 
cytoplasm which is influenced by cell cycle progression and DNA damage 
(reviewed in [118, 119]). While in the cytoplasm, P53 may form complex 
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with antiapoptotic protein Bcl-xl preventing apoptosis, any nuclear P53 
induction will trigger apoptotic proteins e.g. PUMA which itself can traffic 
to cytoplasm and release P53 from the Bcl-xl complex. This leads to 
mitochondrial membrane permeabilization resulting in apoptosis [120]. 
 Secondly, while nuclear translocation of P53 triggers its 
proapoptotic transcriptional function upon treatment with anticancer 
DNA-damaging agents, the same molecule is transported to mitochondria 
upon treatment with a tumour promoting agent, where it inhibits the 
activities of tumour suppressor, Manganese superoxide dismutase [121]. 
P53 is also known to translocate to mitochondria following radiation or 
camptothecin treatment, while APE-Ref1 and BAX, after treatment with 
H2O2 and etoposide respectively [122-124]. Other proteins involved in 
DDR e.g. BRCA1 [125], Chk1 [126], Cdc25A [127] and BID [128] show 
DNA damage induced nuclear export, while still others e.g. Mdmx [129] 
and Optineurin [130] undergo nuclear import following DNA damage. A 
vast majority of proteins including the DDR kinases show intranuclear 
relocalisation upon DNA damage e.g. DNA-PK [131], ATR [132], Mdm2, 
[133] and p14ARF [134]. 
 The ATM kinase was first regarded as a nuclear protein that was 
believed to function mainly in the nucleus as a critical DNA damage sensor 
[71]. Discoveries of ATM’s other functions beyond its well characterised 
role as a nuclear DNA damage sensor kinase was expected to require 
some degree of sub-cellular ATM trafficking.  In terms of ATM’s role in 
cell proliferation, it was shown that upon double-stranded DNA damage, 
a fraction of nuclear phosphorylated ATM underwent protein trafficking 
to the cytoplasm where it activated NFkB [135]. On the other hand, it 
was also shown recently that damage induced DDR was accompanied by 
nuclear import of cytoplasmic pATM following UV treatment [136].
 Interest in characterising the extra nuclear role of ATM was 
triggered by the increasing understanding of the disease phenotype of 
Ataxia Telangiectasia (A-T) patients, caused by deleterious mutations 
in ATM gene (Refer to section 3). ATM deficiency in patients leads to 
cancer susceptibility, weak immune system, hypersensitivity to ionizing 
radiation and sterility while A-T cell lines undergo radio-resistant and 
damage prone DNA synthesis and abnormality in cell cycle checkpoint 
arrest (more details of the A-T disease are given in the following section). 
While these aberrations can straightforwardly be attributed to the role of 
ATM in DDR, other neurological disease phenotypes e.g. ataxia, speech 
defects and abnormal body movements or cellular defects e.g. cytoskeletal 
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abnormalities, plasma membrane defects and high levels of trophic factors 
requirement for growth cannot all be explained through ATM’s role as a 
nuclear DNA damage sensor. 
 These initial questions led to key discoveries, which supported the 
Table 4. Extra-nuclear ATM localisation and the associated function in different cells.
Cell type Cellular compartment Associated function Ref.
Fibroblasts Cytoplasmic vesicles
Found to exist in microsomes. Supported 
a more general role of ATM in cell 
signalling.
[80]
293T cells Cytoplasmic vesicles
Co-localisation with β-adaptin and 
as such may have role in intracellular 
protein traffic mechanisms.
[87]
Human perkinje 
cells Cytoplasm
May implicate the role of ATM in 
neurological homeostasis and thus 
explain the neurodegenerative phenotype 
of A-T patients
[141]
Cerebellocortical 
neurons Endosomes
May have neuronal cell specific role 
as there was higher localisation in the 
endosomes of granule cell neurons than 
Perkinje cells.
[138]
Human 
fibroblasts
Peroxisomes
Co-localisation with catalase enzyme and 
as such may modulate its activity. In A-T 
fibroblasts, increased catalase activity 
was found.
[142]
Murine Perkinje 
cells and dorsal 
root ganglion
Cytoplasm
May be required to prevent lysosomal 
accumulation and have a role in 
maintaining normal cytoplasmic 
organelle function.
[45]
MCF7 Plasma membrane
Co-localisation with Casein kinase-2 
interacting protein-1 which functions in 
muscle differentiation and regulation of 
actin cytoskeleton.
[140]
Neuro-2a Cytoplasm
Forms complex with two synaptic vesicle 
proteins VAMP2 and synapsin-I and 
modulate synaptic function.
[137]
HaCat cells Golgi apparatus
Formed complex with β-COPI coatomer 
protein and underwent rapid nuclear 
transport upon DSB
[99]
Squamous cell 
carcinoma Golgi apparatus
Showed sequential Golgi and nuclear 
shuttling [136]
24
ATM in focus: A damage sensor and cancer target
BioDiscovery November 2012 | Issue 5 | 1
Figure 13. The Ataxia 
Telangi-ectasia (AT) disease 
phenotype. Early symptoms 
include progressive cerebral 
ataxia causing defects in 
motor skills manifested in 
early childhood. This is 
followed by the formation 
of telangiectasia, immune 
defects and predisposition to 
malignancy later in life and 
sterility in adulthood. Patients 
show severe radiosensitivity 
whereby normal doses of 
chemotherapy, to cure cancer 
caused by AT disease, to be 
lethal. Source: [155]. 
role of ATM kinase further than its conventional role in the DDR pathway 
[45, 87, 137, 138]. Table 4 lists the localisation and associated functions of 
ATM in different sub-cellular compartments reported so far, other than its 
nuclear function. 
 It is imperative that such differential localisation of the same 
molecule in different cellular compartments involves rigorous protein 
trafficking events. The fact that ATM has been shown to interact with 
karyopherins [139], found to co-localise with b-adaptin [87], is recruited 
from nucleus to the plasma membrane [140] and the recent discovery of 
sequential localisation of pATM  in Golgi apparatus and nucleus in normal 
human primary keratinocytes as well as in squamous cell carcinoma cell 
lines  after either UV treatment [136] or chemotherapeutic drug [99] also 
supports the idea that ATM undergoes extensive protein trafficking. 
3. Ataxia telangiectasia (A-T) disorder and clinical 
symptoms
The importance of the role of ATM is highlighted by its functional loss in the 
disease, Ataxia Telangiectasia (A-T) also known as Louis-Barr syndrome. 
A-T is a rare autosomal recessive multisystem disorder caused by hereditary 
mutations in the ATM gene. It is the most common recessively inherited type 
of cerebellar ataxia in small children with a frequency of 1 in 50,000 live 
births [143]. 
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 The disease is characterised by ataxia, referring to uncoordinated 
body movements and telangiectasia, which means enlarged blood capillaries 
that can be seen under the skin (fig.13). Other characteristic features of 
A-T include immune deficiency, hypersensitivity to ionizing radiation, and 
a predisposition to certain cancers [144]. Despite the heterogeneity in the 
clinical presentation of the A-T syndrome resulting in the initial finding of 
at least 4 complementation groups [144], the linkage analysis showed that 
they all map to the same genomic location on chromosome 11 (11q22.3) 
containing the ATM gene [37]. 
 Heterozygous carriership of ATM seems to be very common in 
humans, the estimates varying between 1.4 % and 2.2 % of the general 
population and even more common (up to 12.5 %) in populations with a 
marked founder effect [145-147]. A-T patients from nonconsanguineous 
families are usually compound heterozygotes. Carriers of defective ATM 
alleles, although generally considered asymptomatic, have been found to 
have an increased risk of death at any age due to all causes including cancer 
and ischemic heart disease [147]. 
3.1 Neurological features
Most common neurological disorder is progressive cerebellar ataxia, 
which may initially be misdiagnosed as cerebral palsy of the ataxic type. 
It is apparent as early as the first year of a child. Truncal and gait ataxia 
are slowly and steadily progressive. This leads to wheelchair confinement 
in the teenage years. Progression of neurological degeneration continues in 
the adult life without actual mental retardation. Thus, typical A-T patients 
are of normal intelligence, although abnormalities in the motor skills make 
normal learning programs difficult. Abnormalities in the neuronal cells of 
A-T patients include degeneration of Purkinje cells and thinning of the 
granule cell layers and some abnormalities in olivary nuclei and medullary 
tracts [144].
3.2 Telangiectasia
Telangiectasia is the dilation of blood vessels that are visible through the skin. 
Usually telangiectasia appears 2-4 years of the manifestation of neurological 
abnormalities, similar to the ataxia, appearance of telangiectasia is progressive 
as well. First signs of telangiectasia appear mostly in conjunctiva, followed by 
appearance on ears, over nose and behind the knees. These dilated capillaries 
are normally not associated with bleeding. The absence of telangiectasia 
does  not exlcude the diagnosis of A-T. 
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3.3 Radiosensitivity
Radiosensitivity of A-T patients towards ionizing radiation is understandable 
owing to the prominent role of ATM in the desensitization towards genotoxic 
insults. Hence, A-T patients with cancer are extra sensitive to those doses 
of ionizing radiation, which are otherwise employed for non-A-T cancer 
patients and this sensitivity is to a life threatening level. 
 An interesting observation in some A-T patients is the loss of the 
distal 11q region of the chromosome that harbours key DNA damage response 
genes including ATM, MRE11, Chk1 and H2AX in several haematological 
malignancies and solid tumours. At a cellular level, A-T cells, which lack 
detectable ATM, are unable to detect levels of DNA damage which usually 
result in activation of the DNA repair machinery, causing sustained DNA 
damage. Also, they cannot induce cell cycle arrest, resulting in replication 
of damaged DNA and multiplication of errors until the burden of damage 
becomes too severe for the genome. In both cases, the cell is directed to a 
suicide route. Apart from radiosensitivity, A-T cells have abnormal telomere 
morphology and genomic instability [148].
3.4 Cancer predisposition
Cancer predisposition is one of the major complications in A-T with the 
homozygous A-T patients having a life time risk of 30-40 % [149]. The 
correlation between ATM and some forms of cancers have been long 
established with cancer being the most frequent cause of death of A-T patients. 
This link was first observed by Reed WB and colleagues in 1966 who looked 
at incidences of familial and sporadic cancers in homozygous A-T patients 
as well as in heterozygous carriers [150]. Numerous statistical studies have 
been undertaken to form a broader picture to generate a correlation between 
A-T causing mutations and incidences of different kinds of cancers [39, 
151]. There are several reports that attempted to demonstrate links between 
heterozygous and homozygous A-T patients and incidences of familial and 
sporadic cancers. Such correlations have been found in variety of tumours 
to different degrees. This degree of correlation is found to be dependent on 
the type of ATM mutations e.g. missense or nonsense variants and also the 
nature of mutations (germ line or somatic A-T). 
 In line with the finding that A-T patients have a weak immune 
system, the most common malignancy linked with A-T patients is that of 
immune system (Leukemias and Lymphomas) with the most common being 
non-Hodgkin’s lymphoma (~45%) [152] followed by acute lymphocytic 
leukemias (~20%) [153]. This link has further been demonstrated by 
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generating knock out mouse models of ATM shown to be highly susceptible 
to sporadic lymphoid malignancies owing to impairment of the V(D)J 
recombination in such ATM deficient mouse lymphocytes.The lymphomas 
in A-T patients tend to be of B-cell origin, whereas the leukemias are usually 
of T-cell origin. While cancer of the immune system is more common in 
the early lives of A-T patients (mostly occurring in first 15 years), older 
A-T patients are at a greater risk of developing a variety of solid tumours 
including gastric, breast, medulloblastoma and basal cell carcinoma [74]. 
Furthermore, the role of heterozygous carriership of defective ATM alleles 
has been clearly demonstrated in a proportion of familial breast cancer and 
colorectal cancer cases as well [39, 154]. 
4. Role of computational modelling in deciphering DDR 
pathway
Over the past decade, tremendous progress has been in producing qualitative 
signalling data that has improved our qualitative understanding of the signal 
transduction pathways, their molecular mechanisms, activity, regulation and 
the associated outcome on cell-fate. While this has helped us immensely in 
conceptualising intervention strategies in diseased states, the decision making 
property of these pathways may involve oscillations and concentration 
thresholds that require a quantitative approach, calculations and numeral 
analysis for data collection and interpretation. 
 A prerequisite of a molecularly targeted anticancer approach is a 
detailed understanding of the underlying mechanisms contributing in tumour 
development. This involves changes in both the types and extents of molecular 
interactions governing key process in a cell that may predispose it to cancer. 
Additionally, a thorough understanding of the cell microenvironment, 
proliferation, growth and stress signals are vital before a successful anticancer 
approach could be devised. Failure to do so is one reason why theoretically, 
very effective anticancer strategies could be conceptualised, while they still 
fail to actualise. Owing to an intricate nature of context dependent signalling 
networks, high degree of cross-talk and pathway choices and insufficient 
quantitative data of signalling dynamics, a clear inter-relationship among 
cellular signalling to cellular response to its ultimate consequence on 
cellular phenotype has not been fully determined. Until recently, strategies 
for therapeutic intervention via the modulation of key molecular pathways 
targeted individual components of the global regulatory network.  This was 
based on the assumption that different pathways transmit signals through 
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independent mechanisms. However, with the advent of new molecular 
techniques and bioinformatic tools, remarkable progress has been made and 
new insights have been gained into the nature of the intracellular signalling 
networks. 
 It is now known that numerous key proteins have multiple functions 
in different pathways and that the downstream signalling choice of a 
particular protein depends on a number of variables.  ATM is central to a 
number of key pathways as mentioned before. These pathways act in concert 
in order to phosphorylate P53 at a number of sites, some having overlapping 
functions and others being specific for a particular response. In this micro-
environment, the effect of manipulation of DDR in general or inhibiting 
ATM protein specifically is not fully predictable especially owing to the fact 
that ATM function can contribute both in numerous physiological process as 
described in other sections of this book (see section 5). Prediction is further 
complicated by the finding that ATM may self-regulate its own protein levels 
[10, 51, 83]. 
 In this complex and unpredictable scenario, the efficacy of 
potential ATM inhibitors would have to be assessed in terms of the effects 
it exerts, not only on ATM activity and its immediate substrates e.g. 
ATMàpATMàpP53àDNA repair, but on a number of connected key 
proteins in the DNA repair, cell cycle, oxidative stress, protein degradation, 
metabolic signalling, proliferative and apoptotic pathways and their 
associated consequence on cell-fate. It is increasingly becoming obvious 
this complexity in determining the absolute effects of drug intervention 
necessitates parallel theoretical and experimental considerations. This could 
be best addressed by employing a systems biology approach to the problem, 
involving mathematical modelling of biological processes [156-160]. To 
fulfil this, there is a need for collecting quantitative dynamic information 
of DDR signalling proteins at high temporal resolution and identify how its 
sub branches e.g. those controlling DNA repair informs cell cycle regulatory 
network, or how the energy producing pathways are influenced by apoptotic 
signaling and so forth [156, 161]. 
 Mathematical model construction based on information such 
as above would not only provide novel insights into how thresholds, 
localisation and specific interactions of proteins within DDR signalling 
are triggered and regulated during the course of genotoxicity, but would 
also help establish maps of network interactions that would further aid in 
identifying spatio-temporally regulated critical links and their contributions 
in pathways responsible for generating a specific cellular response during a 
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specific treatment regime. Once such critical signalling links are established 
in cancer cells, these could be exploited to devise treatment portfolios to 
achieve targeted cellular sensitivity. Such a model could be capable of 
predicting the global phosphorylation status of important proteins e.g. ATM, 
ATR, P53, E2F1 and BRCA, the activity levels of checkpoint kinases e.g. 
Chk1 and Chk2, a balance between the action of DDR associated kinases and 
phosphatases , pro and anti-apoptotic proteins, and their outcome on cellular 
fate. Also, such a model could be able to provide for varying levels of drug 
input over variable time courses as well as being capable of incorporating 
combinations of intervention strategies e.g. involving both ionizing radiation 
and chemical carcinogens in conjunction with ATM or other DDR protein 
inhibitors. 
 In the past, several researchers have targeted a variety of dynamical 
processes within biological systems for their computational analysis ranging 
from studies into parallel reaction pathways [162], HBV infections [163] and 
in-silico analysis of Sar-CoV [164]. In terms of DDR signalling pathway, 
most of systems biology studies have been undertaken to examine and model 
the oscillatory patterns of DDR protein induction following DNA damage in 
light of the known biological insights [165-168] with some reports focussing 
on elucidating the role of such oscillations in determining cell fate i.e. DNA 
repair, cell cycle arrest or apoptosis [169-172].
 Attempts have also been made to decipher G1/S [173-174] as 
well as G2/M checkpoint engagement upon genotoxic insults [175-176] 
and parallel cell cycle analysis of normal and cancer cells using a Systems 
Biology approach [157-160]. Recently, several system biology attempts to 
elucidate the mechanism of drug resistance to chemotherapy in different 
cancer patients have been informative and uncovered underlying pathway 
alterations driving such drug resistance [177-178]. 
 Systems biology approach for cancer is a new idea and is still in 
infancy. The above research attempts for testing experimental hypothesis 
have made it clear that computational modelling and systems biology 
strategy works best if it is integrated and made an integral component of 
the experimental investigation. Systems biology is a two-way information 
exchange between biology and mathematical modelling. The scheme of this 
relationship is depicted in figure 14 where phase I starts with a biological 
investigation of a problem, data generation and data mining. This data is fed 
into a molecular modelling system, where it not only enables visualization 
of the biological networks in a more understandable and interpretive manner, 
but also allows for its validation, biological appropriateness and suitability 
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and potential for realising biologically observed phenomena. In phase II, 
data simulation takes place and the model identifies key variables, generates 
novel hypothesis, recommends technology development for experiments, 
Figure 14. Pathway for a basic systems biology research. Blue rectangles represent 
mathematical modelling and computer simulation while yellow rectangles represent 
experimental biology.
and proposes areas of interest for further experimentation. The hypotheses 
generated are further tested experimentally taking into account the 
recommendations of variables made in phase II. The data or novel insights 
obtained are further fed back to the model to revise or improve the predictive 
power of the model and generate further hypotheses and further recommends 
technology development for future experimentation in phase-III .
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 In conclusion, previous mathematical modelling attempts have shown 
that the design and construction of a deterministic mathematical model of the 
molecular interactions that underpin the DDR require new kind of time series 
quantitative data. This data must be consistent, have high temporal resolution 
and spatial consideration and provide the kinetic parameters of larger number 
of different proteins involved in a single pathway. The mere descriptive nature 
of the information regarding key cellular pathways has so far limited their 
use in mathematical and computational modelling applications, such as those 
identified in Phase I of the modelling scheme (fig. 14), which could potentially 
identify new therapeutic targets and help us devise treatment regimens. 
While qualitative data are easily available, quantitative data pertaining to key 
signalling molecules that would allow speedy calibrations and provide kinetic 
parameters for the construction of mathematical model is still scarce. 
5. Beyond DNA damage repair: ATM’s role in oxidative 
stress and cellular metabolism.
While ATM activation and function has primarily been characterised in 
response to genotoxic challenge, growing body of evidence suggests its 
functional importance in pathways quite distinct from DNA damage and repair. 
This enables ATM to participate in diverse set of physiological processes 
involving metabolic regulation, oxidative stress, transcriptional modulation, 
protein degradation, cell proliferation and cancer. 
 It has been demonstrated for quite some time that in addition to DNA 
damage, ATM may also be activated under oxidative stress and aging in the 
absence of DNA damage. [179]. This has been shown both in in vitro as well 
as in in vivo studies [180]. The idea that ATM may function in oxidative 
stress response following oxidative damage of macromolecules other than the 
DNA, came from the frequent observation of defects in cellular antioxidant 
systems, elevated reactive oxygen species (ROS) and deregulated levels of 
ROS scavenging enzymes at cellular level, animal models and AT patients. 
It has been demonstrated that cells lacking ATM had an impaired capacity 
to synthesise glutathione [181]. This finding had clear implications of ATM 
in redox signalling pathway. This led to further in vitro investigations in the 
coming years that attempted to discern ATM functioning in oxidative stress 
response which supported ATM’s role in these domains [182, 183]. In another 
report, study of the anti-oxidant capacity of ten A-T patients as compared to 
age matched controls showed a reduced antioxidant capacity and altered levels 
of reactive oxygen species (ROS) scavenging enzymes [184]. 
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 In the same year, in an in vivo study, it was demonstrated that mice 
lacking the ATM gene showed extensive oxidative tissue damage in organs most 
affected by the A-T disease thus providing a mechanistic basis for A-T disease 
phenotype [185]. Interestingly, the oxidative stress induced ATM activation 
without DNA damage. For example, ATM activation and its cytoprotective 
role in oxidative damage was reported following treatments with H2O2 and C2- 
Ceramide, agents that induce oxidative damage of cellular macromolecules, 
without causing chromosomal breaks [186]. A year later, two further in vivo 
studies reported an altered redox state in brains of mice that lacked ATM gene 
[187, 188]. It has been hypothesised that the high oxidative stress, as suggested 
by altered levels of key enzymes, catalase and superoxide dismutase, may 
explain the neuronal degradation observed in A-T patients [187]. Further 
reports of in vitro elucidation of ATM signalling in oxidative stress revealed 
that cells lacking ATM also had defects in oxidative stress induced G1 and G2 
checkpoint function [189]. 
 In keeping with ATM’s role in oxidative stress, further studies showed 
that the phenotypic abnormalities seen in ATM null cell lines could be rescued 
by the addition of antioxidants, thus demonstrating that at least a part of the 
cellular defects seen in ATM null genotypes are because of accumulation of 
oxidative damage [190-192]. Thus, as mentioned, sufficient evidence was 
provided to support the role of ATM in other important physiological processes 
in addition to being a central component in DDR. 
 However, a key question that remained unanswered well until couple 
of years back was how ATM functions as a sensor oxidative stress and gets 
activated not involving DNA damage? The mechanism was thought to be 
more complicated and unique as it was reported that oxidative stress caused 
disruption of DNA binding activity of MRN and hence ruled out MRN 
mediated activation of ATM [77]. The answer was provided by two reports 
in 2010 [77, 78]. According to these reports, intra-cellular oxidative stress 
induced ATM activation by modifying its cysteine residue at position 2991. 
This caused formation of disulphide bond between two ATM monomers 
resulting in formation of active ATM dimers. This was a very novel and 
striking discovery that, contrary to the DNA damage induced ATM dimer to 
monomer activation, occurred in the reverse order. Mutation of this cysteine to 
alanine residue disrupted oxidative stress-induced ATM activation but retained 
its DSB dependent activation. Interestingly, in vitro experiments showed that 
oxidative stress-induced ATM activation did not require DNA, MRN and the 
presence of serine 1981. While treatment with a pro-oxidant H2O2 resulted 
in ATM mediated Chk2 and P53 phosphorylation, it did not cause γ-H2AX 
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formation (marker of DNA damage), or phosphorylation of KAP1 protein, a 
phosphorylation event that occurs following DNA damage [77, 78]. This was 
a key observation showing that oxidative stress or DNA damage induced ATM 
activation may have a complicated interplay and lead to a different subset of 
substrate activation. If such substrates, which are uniquely activated either 
by oxidative stress or DNA damage are identified, this could translate into 
development of biomarkers that can report and distinguish oxidative stress 
induced apoptosis from DNA damage induced apoptosis or other events.
 Nevertheless, making a distinction between these two events is 
Figure 15. Oxidative stress induced ATM signalling pathway. ATM is activated 
following generation of ROS via an active dimer formation involving cysteine 2991 of 
ATM protein. Activated ATM may upregulate p21 levels via P53, which results in nuclear 
accumulation of NRF2 that induces antioxidant response. ATM can also result in NRF2 
activation via PKCδ. Following oxidative stress or insulin treatment, ATM also activates 
AKT by inducing its phosphorylation at serine 473. Activated AKT triggers transport of cell 
surface glucose transporter 4 (GLUT 4) which results in uptake of glucose, activation of 
Glucose-6 phosphate dehydrogenase that generates NADPH, an important cofactor in the 
antioxidant pathway. ATM also directly phosphorylates Hypoxia inducing factor α, which 
via indirect route causes inhibition of mTOR. Furthermore, direct and indirect activation 
of AMPK by activated ATM results in activation of TSC2, which also inhibits mTOR. 
Inhibition of mTOR not only halts cellular proliferation under oxidative stress, but also 
results in inhibition of pathways that carryout oxidative metabolism leading to lowering of 
the oxidative burden on the cell. The figure is designed on the basis of data from [193-197]. 
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complicated by the finding that oxidative stress itself can cause DNA damage 
and there is a great deal of cross talk and overlapping function of proteins. For 
example, 700 proteins have been identified that responded to ATM activation 
following DSBs, not all of which were known for functioning in DDR pathway 
[67]. Figure 15 illustrates most of the oxidative stress induced ATM pathways 
leading to removal of ROS or alteration in metabolic pathways that normally 
produce ROS. 
 The above text described in detail the mechanism and pathways of 
ATM signalling in oxidative stress. Apart from that, it has been shown that 
ATM may have a more general role in other key physiological events as well, 
e.g. cellular homeostasis, mitochondrial function [198], metabolic control 
[199] protein degradation and sumoylation [200] and hypoxia [201]. The fact 
that AT patients have an increased risk of developing type 2 diabetes because 
of Insulin resistance and glucose intolerance suggested ATM’s role in Insulin 
signalling and glucose uptake [202]. The discovery of ATM’s role in regulating 
Insulin like growth factor 1 receptor [203] and ATM dependent AKT activation 
following IR or insulin treatment [195] that results in glucose uptake not only 
served to explain disease phenotype of A-T patients but also supported ATM’s 
role in metabolic signalling pathways. Other studies supporting ATM function 
in cellular metabolism reported the involvement of ATM in pentose phosphate 
pathway that led to generation of Glucose-6-phosphate mediated NADPH 
[196]. One study reported that a mutant P53 devoid of ATM phosphorylation 
site not only resulted in elevated ROS, but also led to insulin resistance 
and glucose intolerance, defects that could be alleviated by the addition of 
antioxidants [204]. ATM mediated AKT activation mentioned above also 
results in activation of mTOR signalling that carries out oxidative metabolism 
resulting in ROS generation. In terms of its modulation of translation, ATM has 
been known to phosphorylate 4EBP1 protein on serine 111 following Insulin 
or IR treatment. 
 This phosphorylation inactivates this protein which otherwise 
represses the translational initiation factor, ELF4E, which then can initial 
translation (Yang DQ et al., 2000).  Moreover, in addition to its role in cellular 
proliferation and survival via the AKT pathway, ATM signals in cytoprotection 
and inflammation pathway through NFkB activation. This represents 
cytoplasmic function of ATM [205]. Activation of AMPK by ATM via LKB1 
dependent [193] and independent mechanisms [206] further establishes ATM’s 
role in cellular homeostasis and metabolic signalling. Under energy crisis, cells 
may accumulate ROS because of depletion of NADPH. 
 Accumulated ROS may activate ATM that further activates AMPK 
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which shuts down energy consuming pathways (proliferation, DNA synthesis 
etc) and triggers catabolic and energy generating pathways (e.g. autophagy 
and mitochondrial biogenesis) as well as NRF2 activation to combat ROS. 
Hence, while Insulin treatment causes ATM mediated AKT activation and 
Figure 16. Role of ATM in 
balancing energy consuming 
and energy yielding pathways. 
Following activation upon Insulin 
treatment or IR, ATM may activate 
AKT pathway which further activates 
mTOR. Activated mTOR inhibits 
autophagy and carries out oxidative 
metabolism by utilising cellular 
energy, which may generate ROS. On 
the other hand, same treatments can 
result in ATM dependent activation 
of AMPK pathway, which yields 
energy by generating ATP, triggers 
autophagy and scavenges for ROS. 
The energy state and degree of ROS 
may determine the type of pathway 
activated downstream of ATM. 
Figure is designed on the basis of data 
from [193, 195]. 
pro-survival signal, upon IR or IGF1 treatment, ATM may activate AMPK 
signal that causes TSC2 mediated mTOR inhibition and cellular arrest. This 
establishes ATM’s role in a critical decision making machinery that is driven 
by energy requirements of the cell and total ROS levels.  A simplified version 
of the signalling pathway that balances ATM activity between pro-survival and 
energy consuming processes that may result in ROS generation and cytostatic 
and energy yielding pathway that scavenges for ROS is presented in figure 16. 
 Another manner by which ATM regulates the metabolism, 
mitochondrial function and angiogenesis is via its modulation of hypoxia 
inducing factor 1 (HIF1). As shown in figure 15, under hypoxic conditions, 
ATM phosphorylates HIF1, which is implicated in the above mentioned 
cellular processes. HIF1 is also known to modulate activities of a protein 
called REDD1. This protein causes sequestration of 14-3-3 proteins from 
TSC2 proteins, thus releasing TSC2 from inhibition and allowing it to inhibit 
mTOR. Hence ATM can modulate metabolic pathways either by modulating 
mTOR activities via AKT and AMPK or through HIF1 activation [197]. 
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6. Novel perspectives: Targeting ATM pathway for 
therapeutic intervention in cancer
Decades of research efforts in attempts to elucidate DNA damage response 
pathways have added significant knowledge to our understanding of the 
mechanisms involved in carcinogenesis, DNA damage and repair pathways, 
and induction of apoptosis. Scientists have described cancer as the disease 
of the cell cycle caused by frequent mutations in cell cycle regulatory 
machinery, proliferative signals and DNA repair enzymes. This definition 
classifies all the proteins functioning in DNA repair, cell cycle progression, 
division, arrest and apoptosis as critical determinants of not only the cancer 
phenotype, but also of the therapeutic approach that is devised to combat it.
 Researchers have realised that cellular sensitivity to genotoxic agents 
in course of cancer therapy could be achieved by modulating the function 
of key proteins involved in DNA repair, cell cycle arrest and apoptotic 
mechanisms. We now know that the efficacy of the gold standard treatments 
of cancer involving chemotherapy and radiotherapy can be further controlled 
and fine-tuned if it is coupled with modulation if the activities of the proteins 
involved in the above mentioned processes. The idea is based on the fact that 
during genotoxic treatments of chemotherapy and radiotherapy, cells respond 
by rapidly upregulating expression and activity of DNA repair and cell cycle 
regulating proteins. The increased activity of these proteins will render such 
cells resistant to genotoxicity owing to rapid repair of the cytotoxic DNA 
lesions and thus hinder the cellular sensitivity process and ensure survival. 
In such circumstances, greater dose of genotoxicity would be required for 
effective killing of these cells. However, increasing the dosage will have 
increased cytotoxic effects on the surrounding normal cells and hence cause 
more side effects of therapy. 
 On the other hand, if the activities of proteins involved in cell 
cycle arrest and DNA repair are inhibited prior to genotoxic treatment, 
greater cellular sensitivity towards genotoxic agents during treatment 
might be achieved. Hence, one important therapeutic strategy for cancer 
is the identification of important DDR protein inhibitors, which could 
effectively inhibit the type of DNA repair machinery that is activated and 
required by cell after a particular genotoxic treatment regimen. Discovery 
and characterization of such inhibitors would not only help to elucidate 
the function of the relevant proteins but could also identify therapeutically 
relevant targets. 
 After validation of specificity and activity of such inhibitors, 
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the next step is to characterise its overall consequence for cellular fate in 
a context dependent manner. This characterisation is important because 
specific inhibitors might still have a wide spectrum of effects on cells. This 
is because proteins participating in DDR and other interconnected pathways 
for example cell cycle, DNA damage, oxidative stress and metabolism, have 
high degree of cross talk and overlapping functions. It is further complicated 
by the fact that many signalling molecules alter substrate preferences and 
hence downstream signalling by variables such as energy state of the cell, 
presence of growth factors, phase of the cell cycle, extent of DNA damage and 
so forth. Hence context dependent treatment regimens have to be formulated 
and proven to be effective in cellular sensitisation in a well characterised 
manner. Having established that, the next key consideration is the selectivity 
of the cytotoxic action towards cancer cells sparing the surrounding normal 
cells. Such selectivity could be achieved by identifying key differences 
between normal and cancer cells and then basing the therapeutic approach 
on exploiting those differences. 
 Cancer cells usually acquire superior epigenetic and genotypic 
changes that may either enhance efficiency of DNA repair machinery, 
handicap the apoptotic pathway, or disrupt cell cycle checkpoint mechanism 
all translating into better survival phenotypes and signalling advantages thus 
rendering cancer cells more accomplished and independent in ensuring their 
survival in emergency situations e.g. during chemotherapy, as compared 
to their normal counterparts. Additionally, such cells usually evolve 
overlapping molecular pathways that can overcome physiological barriers 
and generate the same signalling response as those that are targeted by a drug 
in a particular treatment regimen. Due to this, a prerequisite of employing 
an effective molecularly targeted anticancer therapeutic approach is a full 
elucidation of its complex molecular signalling network driven by these 
genetic and epigenetic alterations. Such critical molecular detailing that may 
be unique for different kinds of tumours may identify genetic weaknesses 
that would not only serve as a biomarker for distinguishing cancerous cells 
from a heterogeneous population of cells, but also for it to be targeted for 
sensitization. This is illustrated in the following example:
 Cancer cells often have mutations in the cell cycle regulating 
proteins and DNA repair abnormalities.  Such aberrations in vital cellular 
functions can potentially make cancer tissues more susceptible to certain 
therapeutic interventions as compared to their normal counterparts. For 
example, in more than 50% of all cancers, P53 mutations have been found 
[207]. This renders the cancer cell incapable of executing the P53-mediated 
38
ATM in focus: A damage sensor and cancer target
BioDiscovery November 2012 | Issue 5 | 1
G1/S cell cycle arrest and the repair of DNA upon genotoxic insults. The 
only checkpoint that is active in such cancer cells is the G2/M checkpoint, 
where the damaged cells are still arrested and repaired, enabling them to 
survive. Therefore, abrogation of this G2/M checkpoint in cancer cells for 
Figure 17. The principle of targeting ATM pathway for achieving cellular sensitivity 
for therapeutic intervention in cancer. Lines with arrow heads indicate activation, while 
lines with bar heads indicate inhibition. Red arrow indicates DNA damage caused by radio or 
chemotherapy while red line with bar head indicates therapeutic inhibition of ATM. Cancer 
cells with P53 loss of function mutation have a dysfunctional G1/S checkpoint whereas 
the G2/M checkpoint may still be functional. When cells are exposed to genotoxic agents, 
DDR pathway is activated which will cause G1/S arrest via P53 pathway and G2/M arrest 
via checkpoint kinases Chk1 and Chk2 pathway. Normal cells can be arrest in either of 
these pathways allowing themselves time for DNA repair. However, cancer cells can only be 
arrested in G2/M pathway via ATM→Chk1/Chk2 pathway. Disruption of G2/M checkpoint 
by way of ATM inhibition would result in failure of cancer cell to arrest in any checkpoint 
making them more sensitive to genotoxic agents while normal cells with functional P53 
would still be arrested and repaired. Source [10]. 
example via ATM inhibition (ATM à Chk1/Chk2 à Cdc25A/B/C à G2/M 
arrest link) would disrupt the only functionally available G2/M checkpoint 
in cancer cells and devoid them of any checkpoint arrest and hence sensitise 
the cells against genotoxic agents (reviewed in [208]). On the other hand, 
the surrounding normal cells would be less affected by this treatment as they 
retain a wild type P53 that can still undergo G1/S arrest. This scenario is 
illustrated in figure 17. This approach provides an opportunity for targeted 
cellular sensitivity based on functional inhibition of ATM kinase.
 In the past, researchers have identified and employed numerous 
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inhibition strategies against DDR proteins in cancer settings and provided 
proof of principle for DDR inhibition-based targeted cellular sensitivity. 
Table 5. Different inhibitors that target the major proteins involved in DNA damage 
response.
Target Compound Ref.
ATM KU55933 [209]
ATM KU60019 [210]
ATM CP466722 [211]
ATR NU6027 [212]
ATM and ATR CGK73 [213]
ATM and ATR Caffeine [214]
DNA-PK NU7441 [215]
DNA-PK LY294002 [216]
ATM and DNA-PK Wortmannin [217]
Chk1 AZD7762 [218]
Chk1 PF-00477736 [219]
Chk1 CEP-3891 [220]
Chk1 LY2606368 [221]
Chk2 C3742 [222]
Chk1 and Chk2 UCN-01 [223]
Chk1 and Chk2 XL-844 [224]
DNA glycosylases and APE1 CRT0044876 [225]
PARP-1 AZD2281 [226]
O6-alkylguanine-DNA alkyl transferase (AGT) O6-BG [227]
Table 5 lists inhibitors targeting the DNA damage response pathway. It 
is noteworthy that many of those listed in the table are either currently in 
clinical trials or have been in clinical trials. For example the Chk1 inhibitors 
AZD7762 and PF-00477736, and the broader spectrum Chk1 and Chk2 
inhibitors UCN-01 and XL-844 as well as the PARP-1 inhibitor AZD2281 
have completed clinical trials whilst the DNA-PK inhibitor, CC-115, the 
alkyl guanine transferase inhibitor, O6 BG, and a specific Chk1 inhibitor, 
LY2606368, are currently recruiting patients for clinical trials.
 In terms of the exploiting DDR pathway for therapeutic intervention, 
the inhibitors of Poly ADP-ribose polymerase-1 have made the greatest 
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progress and many such inhibitors are currently valuated in clinical trials 
[228]. Following the initial discoveries of inhibitors of ATM [214, 217], 
the quest for finding compounds with higher specificity and to test them 
for their therapeutic benefit quickly followed. There are several reports that 
demonstrate increased cellular sensitivity towards genotoxic agents by way 
of modulating the ATM signalling pathway through inhibition of ATM kinase 
specifically. 
 In one of the earliest of such reports, Morgan SE et al (1997) 
demonstrated that over-expression of a truncated version of the functionally 
important leucine zipper domain of the ATM gave rise to a dominant 
negative ATM mutant in colon cancer cells. This group reported that such 
cells had an increased level of radiosensitivity and chromosomal breakage 
and an abrogated S-phase checkpoint. Inhibition of ATM expression, 
brought about by employing ATM antisense RNA and siRNA mediated gene 
silencing, represents another strategy adopted by several researchers. It has 
been demonstrated that attenuating ATM levels in human glioblastoma cells, 
by using antisense RNA against the kinase domain of ATM, increased their 
radiosensitivity independent of the status of P53 [229].  The resulting cells 
showed higher expression of P53 and P21 proteins, aberrant G2 checkpoint 
control and increased radiosensitivity after irradiation with a clinically 
relevant 2 Gy dose. In a similar approach the therapeutic potential of siRNA 
against ATM, ATR and DNA dependent protein kinase for use as radio and 
chemo-sensitizing agent has been assessed against human prostate cancer 
cells [230]. This approach reduced the respective protein levels by 90% 
after 48 hours post treatment, while the sensitivity of the cells to radiation 
was significantly increased. They also confirmed that such siRNA mediated 
silencing was a more potent sensitizing agent then some of the inhibitors of 
these kinases, e.g. wortmannin or LY294002. 
 In another study a negative link between EGF and ATM 
expression has been established and has been observed that the treatment 
of human lymphoblasts and fibroblasts with EGF down regulated both 
ATM and DNA-dependent protein kinases which, in turn, resulted in 
increased radiosensitization in cells with wild type ATM, while no further 
radiosensitization was seen in irradiated A-T cells [55]. The group further 
demonstrated that the reduction of ATM protein levels following EGF 
treatment resulted from transcriptional suppression of ATM at promoter 
level.  
 In another study the link between protein kinase C activator, 
12-O-tetradecanoylphorbol 12-acetate, termed TPA, and the ability of ATM 
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to radiosensitize the otherwise radioresistant human prostate cancer cell line 
and induce apoptosis has been exploited [231]. The above study reported 
that treatment of cells with TPA increased the levels of an apoptotic inducing 
regulatory enzyme ceramide synthase (CS) while caused an accompanying 
decrease in ATM activity, resulting in apoptosis induction after radiation 
treatment. This group also used antisense ATM oligonucleotides to suppress 
ATM expression in cancer cells. This resulted in higher levels of CS activation 
and apoptosis even with low radiation doses of 1Gy in radio resistant prostate 
cancer cells. A-T cells, which are highly chemo- and radiosensitive also have 
a disrupted NF-kappa B expression. Exploitation of this link between ATM 
and NF-kappa B pathway regulation (fig. 10) is an interesting anticancer 
target and experiments have been performed by using both a dominant 
negative form of NF kappa B inhibitor, I Kappa B alpha and inhibitors of 
ATM to disrupt the NF kappa B pathway to achieve chemosensitization and 
apoptosis of cancer cells [232]. 
 Under genotoxic conditions of chemo or radiotherapy, some tumour 
cells undergo a premature senescence also called stress-induced senescence 
[233]. Although this permanent arrest of tumour cells is beneficial and 
prevents tumour metastasis, such senescent tumour cells resist apoptosis 
and may re-enter the cell cycle. Crescenzi et al [234] set out to identify the 
cellular pathways responsible for the maintenance of such drug induced 
tumour senescence in breast, lung and colon carcinoma cells and identified 
the ATM/ATR pathway to be constitutively active in these cells. They 
successfully used the specific ATM inhibitor KU55933 and another ATM 
and ATR inhibitor CGK733 [213] to block this pathway and demonstrated 
increased apoptosis in these cell lines.  Essentially, while this treatment was 
cytotoxic to cancer cells, it did not cause apoptosis in the normal senescent 
human fibroblasts. 
 In another attempt to inhibit ATM, Zou J et al. [235] made use of 
biodegradable nanoparticles coated with ATM antisense oligonucleotides 
and tested this approach to inhibit ATM in cancer cells in vitro as well as 
in head and neck squamous cell carcinoma tumours in vivo. They reported 
that this approach successfully sensitised tumours to radiotherapy.  Recently, 
Neijenhuis S et al [236] reported that lung carcinoma cells expressing an 
aberrant β-Polymerase, a key enzyme in base excision repair, depend on 
homologous recombination repair after IR treatment. In such cells, when ATM 
function was blocked via KU55933 treatment, an increased radiosensitivity 
was achieved because of failure of cells to repair through HRR. In a very 
recent study, Golding SE et al [237] employed the second generation ATM 
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kinase inhibitor KU60019 in a combination treatment with Temazolamide, an 
alkylating agent used for treatment of brain cancer. This group demonstrated 
that combining this reversible inhibitor of ATM with the alkylating agent 
sensitized the otherwise very resistant glioma cells.  Secondly this treatment 
was found to be cancer selective as KU60019 treatment alone did not have 
any growth inhibitory effects on the co-cultured human astrocytes [237].
 Most recently, Roossink F et al [238] demonstrated in vitro as well 
as in cervical cancer patients that cancer cells that showed high levels of 
phosphorylated ATM (active ATM) prior to irradiation showed greater 
radioresistance than those with moderate levels of active ATM. Similarly, 
immunohistochemistry of tumour samples collected from patients with 
advanced stage cervical cancer also strikingly showed that tumours showing 
radioresistance had high levels of active ATM and this was related with 
poor locoreginal disease free survival and shorter disease specific survival. 
Furthermore, inhibition of ATM with the ATM inhibitor KU55933 strongly 
radiosensitised cancer cells without having deleterious effects on non-
transformed epithelial cells. 
6.1. Current challenges
While conceptualization of the ATM inhibition-based anticancer therapeutic 
approach seems straightforward, there are a number of challenges to 
overcome. Although, theoretically such inhibition of ATM function would 
disable the DDR mediated cell cycle arrest and repair and cause accumulation 
of DNA damage leading to cell death, there are other similar kinases with 
overlapping functions with ATM, such as DNA-PK and ATR. Thus, it would 
require a broad spectrum kinase inhibitor to inhibit all important DDR 
kinases. On the other hand, a more general inhibitor may have more off-
target and cytotoxic effects in normal cells, which would lead to increased 
side effects. Secondly, ATM itself can signal to cause apoptosis via P53 
dependent and independent pathways as described earlier, in which case, 
ATM inhibition may rather desensitise the cells against genotoxic agents 
and thus be counterproductive. One example of this is a recent report [10], 
which clearly demonstrated deference in the effects of ATM inhibition on 
survival of cells when exposed to a lower or higher dosage of a radiomimetic 
drug (context dependent difference). A further evidence of an unexpected 
signalling alteration caused by ATM inhibition was provided by another 
report recently [83]. Hence, while designing ATM inhibition based strategy 
for cellular sensitivity against genotoxic agents, it is imperative to consider 
two vital factors: 
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 Firstly, the type of genotoxic agent employed should only trigger 
a DNA repair response for which ATM is a central component with no 
overlapping enzymes activated; hence it solely depends on ATM function. 
This would translate into effective sensitization specifically towards ATM 
inhibition after the genotoxic treatment. Secondly and equally vital is 
to characterise the context dependent role of ATM. As mentioned earlier, 
ATM is a multifunctional protein with signalling roles both in prosurvival 
Figure 18. ATM is a central component of prosurvival and apoptotic pathways. Based 
on cellular context, ATM can either trigger anti-apoptotic pathway where it ensures survival 
or apoptosis. Survival pathway itself can either lead to proliferation via NFkB and ERK and 
AKT signalling, or cell cycle arrest to allow time for DNA repair. In the apoptotic mode, 
ATM may trigger cell death either in P53 dependent or independent manner.
and cytotoxic pathways. Within prosurvival pathways, ATM may function 
in cytoprotection mode by arresting cell cycle and initiating DNA repair, 
or trigger proliferative signals. On the other hand, in cytotoxic pathway, 
ATM may cause permanent cell cycle arrest and apoptosis or E2F1 mediated 
apoptosis without involving cell cycle arrest. Figure 18 illustrates the 
pathways involving ATM and demonstrates its multifunctional nature. Thus 
it becomes critical to determine experimental setting e.g. type of treatment, 
its dosage and time of treatment in order to employ ATM inhibition at a 
precise time point or at a concentration of genotoxic treatment, where ATM is 
functioning to promote cellular resistance towards cell death and apoptosis. 
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 In the light of the above discussion, it has become clear that in order 
to identify and develop novel inhibitors of DDR pathway, there is a parallel 
need for identification of novel biomarkers of signalling activity of any given 
component in the DDR pathway. These biomarkers should be responsive 
to the inhibitors and should report the action of the inhibitors on the target 
proteins. Furthermore, in an ideal situation, these biomarkers should be 
characterised and validated for reporting the most vulnerable cellular states 
in terms of the therapy and inhibition, which could be dictated by the redox 
status of the cell, phase of the cell cycle or metabolic activity. This feature of 
DDR manipulation strategy is further elaborated in the next section. 
6.2. Future direction
While increasing understanding of the aetiology of cancer has served 
to answer many questions, it has also generated numerous new ones. 
Characterisation of multifunctional signalling molecules has made it 
quite clear that each node in a network of signalling pathway represents 
several pathway choices that could generate or contribute in overlapping 
or often different and context dependent cellular response to a drug. This 
is complicated by the fact that owing to a complex networking nature of 
cellular signals, the complement of genetic mutations within a tumour 
may influence pathway preferences of  multifunctional proteins in a given 
treatment protocol. 
 The future research endeavours should focus on elucidating 
the state of key decision makers in this intricate network of signalling 
molecules in different cancers. Such research attempts would not only shed 
light on the multifunctional molecules inducing pathway preferences that 
would explain altered cellular responses of cancer and normal cells to the 
same treatment regimes, but would also allow for the manipulation of such 
network linkages and decision making nodes in the pathway. We believe 
that a prerequisite to get to such level of molecular detailing is a generation 
of novel biosensors and detection techniques that are highly sensitive 
and allow for high throughput mode of detection of both behaviour of 
individual pathway components as well as overall physiological changes 
within the cell. There are numerous examples of biosensors and in situ DNA 
damage detection methods in the literature surrounding different signalling 
component of the DDR pathway. Key recent biosensors surrounding ATM 
and most prominent DNA damage detection techniques are summarised 
in table 6. With regard to drug development, of particular interests are 
biosensors, which can monitor activity of key target enzymes such as 
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Table 6. Biosensors of DDR pathway and assays for detection of DNA damage. 
Assay Type Method Description Ref.
DNA damage 
detection
Fluorescent 
based/Flow 
cytometry 
detection
Novel γ-H2AX assay for DNA 
damage detection in adherent and 
non-adherent cells
[241]
Biosensor of 
ATM activation
FRET FRET based ATM activation assay 
involving ATM and CHK2
[242]
Biosensor of 
ATM inhibition
Fluorescent and 
Luminescence
Reports an induction of ATM 
transcription upon its kinase 
inhibition.
[83]
Biosensor of 
DNA damage 
inducers
Fluorescent 
based assay
Quantitative cell based high content 
analysis for screening activators 
of DNA damage based on CHK2 
activation.
[243]
Biosensor of 
ATM activation
HRP based 
ELISA/
Fluorescent 
assay
DNA damage induced foci detection 
of YFP tagged ATM combined with 
ELISA based high throughput array 
for DDR protein phospho induction
[75]
Monitoring 
kinase activity 
and inhibition in 
live cells
Luciferase-
conjugated  
kinase 
substrates
Utilisation of genetically engineered 
cells expressing  luciferase-
conjugated kinase substrates  to 
monitor activity of kinase inhibitors 
in  live cells. 
[240, 
244]
Biosensor of 
ATM activation
Luminescence ATM promoter tagged with 
Luciferase gene
[83]
Detection 
of apoptosis 
associated DNA 
breaks
TUNEL assay Labelling DNA breaks using 
terminal transferase
[245]
Detection of 
DNA damage
In situ nick 
translation
Detection of DNA damage in tissue 
sections
[246]
Detection 
of apoptosis 
associated DNA 
breaks
Comet assay/
Single cell 
electrophoresis
Detection of DNA breaks in agarose 
trapped cells
[247]
Detection of 
DNA damage
FISH assay Fluorescent In situ hybridization 
assay for detection of DNA damage
[248]
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kinases in real time in live cells. Since phosphorylation often modulate 
stability of protein substrates [239] genetically engineered cells expressing 
luciferase-conjugated  kinase substrates can be utilised as biomarkers and 
biosensors  to monitor activity of kinase inhibitors in live cells [240].
 The new generation of biosensors should not only report the activity 
of a molecule, for example kinase activity of ATM during a treatment 
regime, but should also inform us of the pathway preference of ATM once 
activated or report a change whenever it switches its multifunctional nature 
of signalling between, for example, cell cycle arrest or proliferation, DNA 
repair or apoptotic induction, ROS generating pathway or ROS scavenging 
(see figures 16 and 18). This would not only allow to monitor enzymatic 
activity of critical enzymes in DDR, but would also report in real time how 
and when pathway choices are made by enzymes implicated in dual or 
multiple functions. However, a mere reporter of an enzymatic induction or 
inhibition or a biosensor of DNA damage (e.g. those listed in table 6) fails 
to serve the above mentioned critical detailing. 
 A way to create such biosensors is to design an assay that reports 
changes in a signalling branch rather than a signalling component i.e. an 
assay that is based on the activation of a signalling link emerging from a 
single molecule rather than a mere activation or inhibition of that molecule. 
This could be done in the form of reporting real time protein-protein 
interaction that necessitates a cellular response or senses the formation 
of a complex of proteins that is a commitment to only a specific cellular 
outcome. This is based on the principle that multifunctional proteins 
contribute in multiple pathway signalling by altering their substrate 
preferences depending upon the state of cell health. Additionally, these 
biosensors should also incorporate information from protein trafficking 
and localisation changes. There are numerous proteins whose downstream 
signalling preference depends upon their cellular localisation at a given 
time. Hence tightly coupled to induction and inhibition is anterograde and 
retrograde transport that would lead to either sequestration or complex 
formation for an enzyme with its substrate. Recently, in terms of ATM 
signalling, it was found that it undergoes DNA damage induced Golgi 
to nuclear transport. This trafficking event led to nuclear accumulation 
of pATM and pP53 Ser 15 [99]. This change in ATM localisation (upon 
activation of its DDR function) may have consequences for cytoplasmic 
component of its signalling pathway (implicated in proliferation and ROS 
generation), e.g. NFkB signalling and in mTORC regulation [193]. Hence, 
a biosensor that reports these changes in addition to induction or inhibition 
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will be more predictive of the cellular response upon drug intervention.
 Such biosensors once designed and validated could then be used to 
carry out signal profiling of premalignant and malignant tumours isolated 
from patients. This could be done by exposing them to test treatment 
protocols and determine the behaviour of multifunctional proteins e.g. 
ATM, that may differ greatly both in induction kinetics as well as pathway 
choices on the basis of the complement of genetic mutations in the 
tumour. Based on data from the biosensor, post treatment predictions of 
signalling behaviour and ultimate cellular response to therapy could be 
made, protocols could be fine-tuned to a therapeutic window and optimal 
treatment regimens devised for the actual therapy with lowest cytotoxic 
effects on normal tissues. 
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